Literature DB >> 1997110

Critical factors for the reversal of methotrexate cytotoxicity by folinic acid.

S Bernard1, M C Etienne, J L Fischel, P Formento, G Milano.   

Abstract

The cytotoxicity of methotrexate (MTX) on representative human tumour cell lines (two cell lines from head and neck carcinomas, two from breast carcinomas, two from osteosarcomas and one lymphoblastoid cell line) was evaluated to: (1) examine the optimal time interval between MTX and folinic acid (FA) administration; (2) determine the critical FA/MTX concentration ratios; and (3) compare the relative effects of the equimolar mixture d,I-FA and I-FA. The cytotoxic effects of MTX were assessed by the MTT semi-automated test. For all of the cell lines tested, a significant inverse relationship was noted between the degree of MTX cytotoxicity reversal and the duration of the time interval between MTX and FA administration. Overall an 18-24 h interval between MTX and FA represented a time-threshold after which MTX effects could not efficiently be reversed by FA in most cell lines. With shorter time intervals between MTX and FA, MTX cytotoxicity could be partially on even totally reversed by FA; the intensity of reversal varied among the cell lines tested, and depended on the FA/MTX ratio. Regardless of the interval between MTX and FA, analysis of the various FA/MTX ratios revealed a significant direct relationship between this ratio and the percentage of recovery. Presence of the d-form had no influence on the MTX rescue capacity of the I-form; this suggests that the presence of the d-FA is unlikely to have any significant clinical consequences.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1997110      PMCID: PMC1971778          DOI: 10.1038/bjc.1991.70

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  22 in total

1.  Clinical pharmacology of the stereoisomers of leucovorin during repeated oral dosing.

Authors:  R L Schilsky; K E Choi; E E Vokes; A Guaspari; C Guarnieri; S Whaling; M A Liebner
Journal:  Cancer       Date:  1989-03-15       Impact factor: 6.860

2.  Lack of interference by the unnatural isomer of 5-formyltetrahydrofolate with the effects of the natural isomer in leucovorin preparations.

Authors:  R Bertrand; J Jolivet
Journal:  J Natl Cancer Inst       Date:  1989-08-02       Impact factor: 13.506

3.  A comparative study on the pharmacokinetics of methotrexate in a dose range of 0.5 g to 33.6 g/m2 in children with acute lymphoblastic leukemia.

Authors:  J D Borsi; P J Moe
Journal:  Cancer       Date:  1987-07-01       Impact factor: 6.860

Review 4.  High-dose methotrexate: a critical reappraisal.

Authors:  S P Ackland; R L Schilsky
Journal:  J Clin Oncol       Date:  1987-12       Impact factor: 44.544

5.  Lack of correlation between methotrexate concentrations in serum, saliva and sweat after 24 h methotrexate infusions.

Authors:  H Schrøder; K B Jensen; M Brandsborg
Journal:  Br J Clin Pharmacol       Date:  1987-10       Impact factor: 4.335

6.  Two new human tumor cell lines derived from squamous cell carcinomas of the tongue: establishment, characterization and response to cytotoxic treatment.

Authors:  J Gioanni; J L Fischel; J C Lambert; F Demard; C Mazeau; E Zanghellini; F Ettore; P Formento; P Chauvel; C M Lalanne
Journal:  Eur J Cancer Clin Oncol       Date:  1988-09

7.  Comparison of intra-arterial cis-diamminedichloroplatinum II with high-dose methotrexate and citrovorum factor rescue in the treatment of primary osteosarcoma.

Authors:  N Jaffe; R Robertson; A Ayala; S Wallace; V Chuang; T Anzai; A Cangir; Y M Wang; T Chen
Journal:  J Clin Oncol       Date:  1985-08       Impact factor: 44.544

8.  High-dose methotrexate therapy with leucovorin rescue: in vitro investigations on human osteosarcoma cell lines.

Authors:  H Diddens; T Teufel; D Niethammer
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

9.  Altered pharmacokinetics and clinical consequences of low dose methotrexate plus cisplatin in the treatment of advanced head and neck cancer.

Authors:  G Milano; A Thyss; N Renée; J Vallicioni; J Santini; M Schneider; F Demard
Journal:  Eur J Cancer Clin Oncol       Date:  1986-07

10.  A study of some variables in a tetrazolium dye (MTT) based assay for cell growth and chemosensitivity.

Authors:  P R Twentyman; M Luscombe
Journal:  Br J Cancer       Date:  1987-09       Impact factor: 7.640

View more
  3 in total

1.  Influence of genetic polymorphisms in the folate pathway on toxicity after high-dose methotrexate treatment in pediatric osteosarcoma.

Authors:  Jeong A Park; Hee Young Shin
Journal:  Blood Res       Date:  2016-03-25

2.  Mechanism of Action of Methotrexate Against Zika Virus.

Authors:  Sungjun Beck; Zhe Zhu; Michelli F Oliveira; Davey M Smith; Jeremy N Rich; Jean A Bernatchez; Jair L Siqueira-Neto
Journal:  Viruses       Date:  2019-04-10       Impact factor: 5.048

3.  Glucarpidase to combat toxic levels of methotrexate in patients.

Authors:  Jacalyn M Green
Journal:  Ther Clin Risk Manag       Date:  2012-11-22       Impact factor: 2.423

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.